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cohort Profile: The Danish  
Testicular cancer late Treatment 
effects cohort (DaTeca-laTe)
Michael Kreiberg1*, Mikkel Bandak1, Jakob Lauritsen1, Julie Wang Skøtt1,  
Nanna Borup Johansen2, Mads Agerbaek3, Niels Vilstrup Holm4, Christoffer Johansen1,5 
and Gedske Daugaard1
1 Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2 Research Centre 
for Prevention and Health, Centre for Health, Glostrup, Denmark, 3 Department of Oncology, Aarhus University Hospital, 
Aarhus, Denmark, 4 Department of Oncology, Odense University Hospital, Odense, Denmark, 5 Unit of Survivorship, Danish 
Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
The cohort was set up in order to analyze late effects in long-term testicular cancer 
survivors (TCS) and to contribute to the design of future follow-up programs addressing 
and potentially preventing late effects. Data for this cross-sectional study were collected 
between January 1, 2014, and December 31, 2016, among living Danish TCS and 60% 
agreed to participate in the cohort (N = 2,572). Mean time since testicular cancer (TC) 
diagnosis was 18 years (range 7–33) and mean age of participants was 53 years (range 
25–95). Data consist of results of a questionnaire with patient reported outcomes which 
covers a broad range of items on late-effects. The study also included data obtained 
through linkages to Danish registries, a biobank, and clinical data from hospital files and 
pathology reports originating from the Danish Testicular Cancer Database (DaTeCa). 
The treatment during the observation period has been nearly the same for all stages 
of TC and is in agreement with today’s standard treatment, this allows for interesting 
analysis with a wide timespan. We have extensive data on non-responders and are able 
to validate our study findings. Data from a Danish reference population (N = 162,283) 
allow us to compare our findings with a Danish background population. The cohort can 
easily be extended to access more outcomes, or include new TCS. A limitation of the 
present study is the cross-sectional design and despite the large sample size, The Danish 
Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE) lacks statistical power to 
study very rare late effects. Since it was voluntary to participate in the study we have some 
selection bias, for instance, we lack responders who were not in a paired relationship, 
but we would still argue that this cohort of TCSs is representative for TCSs in Denmark.
collaboration and data access: Researches interested in collaboration with the 
DaTeCa-LATE study group please contact Professor Gedske Daugaard kirsten.gedske.
daugaard@regionh.dk.
Keywords: testicular cancer, germ cell cancer, cohort profile, cohort study, cancer late effects, late effects
inTrODUcTiOn—WhY Was The cOhOrT seT UP?
In industrialized countries, testicular cancer (TC) is the most common solid tumor in men between 
20 and 40 years of age. In Denmark, the age standardized incidence rate per 100,000 person-years 
is 9.9 which corresponds to 300 incident cases annually (1, 2). TC is a highly curable tumor with a 
5-year survival of 95–98%, which results in an increased population of long-term testicular cancer 
FigUre 1 | The Danish Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE) cohort design.
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survivors (TCS). However, treatment is hampered by late effects, 
including increased risk for secondary cancer (3, 4), metabolic 
syndrome (5), cardiovascular disease (6), neurotoxicity (7), sexual 
dysfunction (8), and psychosocial problems (9). Nevertheless, our 
current knowledge of risk factors, the related health problems and 
the quality of the posttreatment life remains insufficient to fully 
optimize individual programs designed to address and reduce 
long-term toxicity and improve quality of life in TC survivors.
Historically there have been small variations in standard TC 
treatment in Denmark, and now it is completely harmonized 
in national multidisciplinary guidelines for treatment and 
follow-up carried out at three university hospitals responsible 
for this patient group. The treatment algorithm is as follows: (a) 
patients with disease confined to one or both testicles (stage I 
disease) are treated with orchiectomy followed by surveillance, 
and approximately 75% of stage I patients are cured by this 
treatment alone (10, 11); (b) patients with seminoma histology 
and limited retroperitoneal disease are offered treatment with 
radiotherapy (RT) or chemotherapy; (c) in the remaining patients 
with disseminated disease, chemotherapy with three or four 
courses of bleomycin, etoposide, and cisplatin (BEP) is the treat-
ment of choice depending on prognostic group; and (d) a mino-
rity of patients, approximately 5%, will need more than one line of 
treatment (MTOL) due to progressive disease or disease relapse.
In order to clarify late effects related to treatment, apart from 
orchiectomy, we have chosen, where appropriate, to use the 
surveillance group (stage I TC) as a reference group.
The Danish Testicular Cancer Late Treatment Effects Cohort 
(DaTeCa-LATE) consists of a combination of data derived from 
the clinical database DaTeCa (1984–2007) (11), national health 
and sociodemographic registries (1977–2016), a biobank with 
blood and sputum samples, and an 167-item questionnaire con-
taining patient reported outcome measures (PROMs) obtained in 
2014–2016. The cohort design is illustrated in Figure 1.
The cohort was set up in order to analyze treatment-related 
late effects in TCS and to contribute to the design of future follow-
up programs addressing and potentially preventing late effects in 
long-term TCS.
The Danish Testicular Cancer Late Treatment Effects Cohort 
is a nationwide and population-based cohort and is located at the 
Department of Oncology, Rigshospitalet, Copenhagen University 
Hospital, Denmark.
WhO is in The cOhOrT?
In 2014, we accessed the DaTeCa database, which at that time 
included some 7,500 TC patients. Patients in the database 
have been identified through the Danish Cancer Register 
and hospital files. In the present study, we included 5,367 of 
these patients treated in the period between January 1, 1984, 
and December 31, 2007, as we aimed for a long observational 
period facilitating the study of late effects. The mean time since 
diagnosis is 18  years (range 7–33). Inclusion criteria in the 
DaTeCa database covers the diagnosis of a germ cell cancer 
(International Classification of Diseases, 10th revision, ICD-
10: DC 62.1-62.9, DC38.3, and DC48.0, the latter two together 
with germ cell histology), Danish citizenship, follow-up and 
medical treatment conducted at an oncology ward in Denmark. 
The overall coverage in the database is approximately 80% (11). 
In the DaTeCa database, we identified a total of 4,271 TCS eli-
gible for participation in DaTeCa-LATE. The main reasons for 
exclusion of patients (N = 1,096) are presented in the flowchart 
(Figure 2).
A postal invitation to participate was sent out to all eligible 
TCS in November 2014. Following written informed consent, 
patients filled in a questionnaire either in a paper version or 
electronically. Reminder postal invitations were sent out to non-
responders and non-responders were also reached by phone. 
FigUre 2 | The Danish Testicular Cancer Late Treatment Effects Cohort 
(DaTeCa-LATE) flowchart.
Table 1 | Characteristics of responders included in DaTeCa-LATE and 
non-responders.
characteristics responders,  
no. (%) 2,572 (60)
non-responders, 
no. (%) 1,699 (40)
P-Value
Age treatment (years) <0.001
Mean 35 34
SD 10 9
Age attained (years) <0.001
Mean 53 52
SD 11 11
Time since diagnosis (years) 0.014
Mean 18 17
SD 7 7
Decade of treatment, no. (%) 0.051
1980s 514 (20) 289 (17)
1990s 1,126 (44) 773 (46)
2000s 932 (36) 637 (37)
Treatment, no. (%) <0.001
Surveillance 1,174 (46) 947 (56)
BEP 896 (35) 441 (26)
RT 323 (12) 236 (14)
MTOL 85 (3) 27 (1)
Othera 94 (4) 48 (3)
Histology, no. (%)b 0.384
Seminoma 1,370 (53) 935 (55)
Nonseminoma 1,201 (47) 764 (45)
Comorbidity, no. (%) 0.190
No comorbidity 2,207 (86) 1,424 (84)
One or more comorbidities 365 (14) 275 (16)
Place of living, no. (%) 0.444
Urban 857 (33) 547 (32)
Rural 1,715 (67) 1,152 (68)
Marital status, no. (%) <0.001
Paired relation 1,697 (66) 911 (54)
Single, separated, 
divorced, widower
875 (34) 788 (46)
Age treatment, age attained. and time since diagnosis were compared with 
independent t-test. Column proportions were compared through chi-squared analysis.
aMetachronous and synchronous.
bExtragonadal primary (N = 123).
BEP, bleomycin, etoposide, cisplatin; RT, radiotherapy; MTOL, more than one line of treatment.
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By December 31, 2016, a total of 2,572 (60%) of questionnaires 
distributed was filled in and returned, and this number of TCS 
make up the DaTeCa-LATE study population.
Data on TCS non-responders were collected from the DaTeCa 
database and Danish registries for comparison with responders. 
As illustrated in Table  1 responders were younger at time of 
treatment (34 vs. 35 years) and attained age (52 vs. 53 years) than 
non-responders (P < 0.001).
The response rate was dependent on treatment modality. As 
such, the response rate was 55% in TCS followed on a surveillance 
program, 67% in TCS treated with BEP, 58% in TCS treated with 
RT, and 76% in TCS treated with MTOL. These data suggest that 
more intensive treatment lead to a higher response rate. Another 
difference observed, concerns marital status. TCS living in a 
paired relation had a response rate of 66% compared to men who 
were single, separated, divorced, or widowed with a response 
rate of 54% (P < 0.001). No difference between responders and 
non-responders were observed concerning decade of treatment, 
histology of the tumor, comorbidity at time of filling in the ques-
tionnaire and place of living.
As a reference population we use data obtained from the 
Danish National Health Profile survey from 2013 based on five 
regional stratified random samples and one national random sam-
ple. A total of 300 450 individuals, aged 16 or older, were invited to 
participate with a response rate of 54% (162,283 individuals) (12). 
As many of the outcomes in the Danish National Health Profile 
Table 2 | Outcomes measured in DaTeCa and DaTeCa-LATE surveys.
sources Outcomes
DaTeca
Clinical data
1984–2015 Hospital files Stage (prognostic group, metastatic site), treatment, relapses, kidney function,  
lung function, pathology reports, ototoxicity, neurotoxicity, smoking at diagnosis 
Registry data
1977– The Danish National Patient Registry Comorbiditya
1984– The Danish Cancer Registry Diagnosis, histology
1993– The Danish In Vitro Fertilization Register Help to achieve pregnancy with spouse
1995– The Danish National Prescription Registry Use of medication
1984– The Danish Register of Causes of Death Cause of death
2014 The Danish Civil Registration System Marital status, place of living, birthplace, migration
1984– The Danish Pathology Register Tumor characteristics
DaTeca-laTe
PROM
2014–2016 Fatigue Multiple fatigue inventory (MFI-20)
Quality of life EORTC QLQ-C30
Anxiety and depression Hospital anxiety and depression scale (HADS)
Psychological distress Perceived stress scale (PSS)
Demographics Education level, occupation, income
Alcohol and tobacco Type, duration and frequency
Substance abuse history Amphetamines, cocaine, heroin, hallucinogens, marijuana, barbiturates, ecstasy, steroids
Health Self-rated, behaviors. Type and frequency in use of medication. Height, weight
Exercise Type, frequency, self-rated physical health
Family history Medical diagnoses in first- and second-degree relatives
Pain Localization, intensity
Neurotoxicity FACT/GOG-NTX subscale
Infertility before and after testicular cancer diagnosis Use of sperm bank, children, type and use of medical help
Symptoms of testosterone deficiency and erectile dysfunction International Index of Erectile Dysfunction (IIEF-15)
Medical history and symptoms Use of medication, diseases in relatives, respiratory symptoms
Biobank
2014–2016 Blood and sputum Future genetic analyses
aSince 1993, where all data are registered according to ICD10.
PROM, patient reported outcome measures.
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survey are the same as in DaTeCa-LATE this allows for a straight-
forward comparison with the reference population, concerning 
the following demographic variables and outcomes: alcohol 
consumption, smoking, education, age, self-rated health, physical 
activity, perceived stress, physical function, and body mass index.
In the present study, continuous variables were compared with 
independent t-tests while column proportions were compared 
with chi-squared analysis. Statistical analyses were performed by 
using SPSS 22.0 (SPSS, Chicago, IL, USA).
The regional ethical committee of the Capital Region of 
Denmark approved the study (file number, H-2-2012-044).
The collection and use of questionnaire data from the refer-
ence population were approved by the five regional data protec-
tion agencies.
This report covers cross-sectional data obtained at December 
31, 2016, only.
WhaT has been MeasUreD?
Variables in DaTeCa-LATE were chosen based on literature 
describing late effects in TCS together with clinical experiences 
concerning late effects in cancer patients. Table 2 gives an over-
view on variables in DaTeCa-LATE in addition to the variables 
originating from the DaTeCa database.
hOsPiTal Files anD PaThOlOgY 
rePOrTs
Clinical data in DaTeCa-LATE are obtained from hospital files 
and pathology reports and are available from the DaTeCa data-
base (11), and depending on stage and treatment, more than 300 
variables are available covering histology, stage, tumor markers, 
treatment, relapses, kidney function, and lung function.
Danish regisTries
Since April 1968, every Danish resident has been assigned 
a unique civil personal 10-digit registration number. Each 
individual is identified with this number and it can be linked to 
different health-related and sociodemographic registries.
Seven different Danish national registries have for now con-
tributed to DaTeCa-LATE. From the Civil Registration System 
(13), we retrieved the dates of migration and cohabitation status, 
information on comorbidity were collected using The National 
Patient Registry (14), and The Danish Cancer Registry provided 
information on cancer diagnosis in order to identify the patients 
(15). Combining hospital files including pathology reports and 
data from the Danish Pathology Register data on tumor charac-
teristics were obtained (16).
Table 3 | Perceived stress scale (PSS), total scores.
Testicular cancer 
survivors
reference 
population
P-Value
PSS mean total score 11.6 10.7 <0.001
SD 6 7
No. 2,545 69,438
PSS mean total score compared with independent t-test.
FigUre 3 | Testicular cancer survivors perceived stress scale (PSS) scores categorized in age groups and allocated into quartiles according to reference group 
quartile PSS scores.
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The Danish in Vitro Fertilization Register provided informa-
tion on help to achieve pregnancy (17), from the Danish National 
Prescription Registry knowledge of prescribed medications have 
been obtained (18), and by linkage to the Registry of Causes of 
Death we obtained the dates and causes of death (19).
PaTienT rePOrTeD OUTcOMe 
MeasUres (PrOM)
The abovementioned questionnaire contain PROMs concerning 
quality of life (EORTC QLQ-30) (20), fatigue (Multiple Fatigue 
Inventory) (21), symptoms of testosterone deficiency and erectile 
dysfunction (International Index of Erectile Dysfunction) (22), 
psychological distress [perceived stress scale (PSS)] (23), depres-
sion and anxiety (hospital anxiety and depression scale) (24), 
and neurotoxicity (FACT/GOG-NTX) (25). Additional PROM 
outcomes are education, occupation, income, alcohol, tobacco, 
drug use and abuse, self-rated health, physical activity, anthropo-
metrics, pain, and infertility.
biObanK
A total of 430 TC patients treated with chemotherapy have 
contributed with DNA samples derived from sputum or blood 
in order to identify predictive genetic markers for long-term 
toxicities. Furthermore, in 2012, additionally 245 TC patients had 
provided serum, plasma and DNA samples for the Danish Cancer 
Biobank (26), and since then nearly all TC patients have provided 
samples for later analyses.
PreViOUs, OngOing, anD PlanneD 
sTUDies
We have previously reported that patients followed on surveil-
lance are at no higher risk for a new primary cancer compared to 
the background population (3), while this is the case for patients 
treated with chemotherapy, RT, or MTOL for disseminated 
disease, who also have increased mortality compared to patients 
with stage I disease (3, 27). Furthermore, we have found that renal 
and pulmonary toxicity related to treatment is partly reversible 
(28, 29). Risk of late relapses is low in surveillance patients, who 
carries a good prognosis (30, 31). Additionally, we have shown that 
patients with preexisting Leydig cell dysfunction are at increased 
risk of testosterone deficiency following treatment (32–34).
A new finding from DaTeCa-LATE is that TCS have higher 
PSS scores than the reference population. This is illustrated in 
Table 3, where mean PSS scores were compared between TCS and 
the reference population with independent t-test. No cutoff values 
exist for PSS, but generally a score of 15 or above is considered as a 
high stress level (35). In Figure 3, TCSs PSS score was categorized 
in age groups and allocated into quartiles according to reference 
group quartile PSS scores. Confined to TCS < 65 years of age we 
found a higher level of perceived stress compared to the reference 
population. In total, 16–19% of TCS < 65 years of age had PSS 
scores in the lowest quartile, while 53–64% had PSS scores in the 
two highest quartiles.
To further elaborate on this primary analysis of PSS, we plan 
comparison of TCS level of perceived stress and lifestyle factors 
(physical activity, smoking, and alcohol consumption) with the 
reference population. In addition we will compare PSS scores of 
TCS with survivors of other cancer types.
Planned studies from DaTeCa-LATE include evaluation 
of quality of life and sexual function in bilateral TC as well as 
analysis of quality of life, education, psychiatric diseases and drug 
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abuse, fatigue, sexual function, and paternity rate stratified on 
treatment modality and compared with a non-cancerous refer-
ence population when applicable. In addition, genetic differences 
related to toxicity and more rarely explored late-effects will be 
investigated.
Statistical analyses will be performed using SPSS (SPSS, 
Chicago, IL, USA) and R software (R Core Development Team, 
Vienna, Austria).
We plan an additional follow-up survey of the cohort after 
5–10  years as well as an extension adding more recently diag-
nosed cases of TC.
WhaT are The Main sTrengThs anD 
WeaKnesses?
The Danish Testicular Cancer Late Treatment Effects Cohort is 
the largest cohort of TCS with a long observation period since 
diagnosis and treatment. The study is nationwide and popula-
tion based which together with the long time since diagnosis 
leads to a high degree of reliability of the results obtained in vari-
ous studies. The study includes a combination of an excessive 
number of clinical data, comprehensive PROM data, and access 
to various administrative register data established indepen-
dently of the hypothesis under study. This type of data almost 
completely avoid the possibility that selection, information as 
well as recall bias influence the results, securing a high validity 
of the observations.
The treatment during the observation period has been nearly 
the same for all stages of TC and is in agreement with today’s 
standard treatment. Patients responding to the questionnaire can 
be compared with non-responders and a reference population. 
The cohort can easily be extended to assess additional outcomes, 
or include new TC patients.
A possible limitation is the differences observed in age, 
marital status and treatment modality between responders and 
non-responders of the questionnaire. However, the absolute dif-
ference in age is negligible and the proportion of patients treated 
with surveillance, BEP and RT is representative of today’s TC 
treatment pattern. Thus, we do not expect that these differences 
will influence the interpretation of PROM data. The difference in 
marital status with more responders than non-responders living 
in a paired relation is in accordance with the findings of other 
similar studies (36), and the finding can be problematic in special 
cases, but overall we find that this cohort of TCSs is representative 
for TCSs in Denmark.
As >95% of TC patients become long-term survivors, survivor 
bias is generally not a limitation. However, as the mortality is high 
in the MTOL group, interpretation of especially PROM data 
among these patients should be done with caution, as they might 
represent a highly selected group of TC who have survived several 
lines of TC treatment. Despite the fact that TC is a rare tumor 
implying that some rare outcomes would be difficult to inves-
tigate, the advantages of the information in this large cohort of 
TC provide a data set that is highly interesting for future studies.
can i geT hOlD OF The DaTa? Where 
can i FinD OUT MOre?
The DaTeCa-LATE steering group welcomes collaboration and 
the interest of national and international colleagues. External 
researchers can get access to data by a collaboration agreement 
with the DaTeCa-LATE steering group. For more information on 
how to apply, please contact Professor Gedske Daugaard, kirsten.
gedske.daugaard@regionh.dk.
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